Premier Laser Systems
This article was originally published in The Gray Sheet
Executive Summary
Crossroads LLC is hired to assist "in identifying and assessing strategic and financial alternatives," the firm announces Feb. 16. Irvine, California-based Premier has placed 54 of its 80 employees on "temporary unpaid leave" due to "short term liquidity issues." Premier's previously planned merger with Ophthalmic Imaging Systems has been terminated by OIS, and the firms note it is "not practicable at this time" (1"The Gray Sheet" Nov. 1, p. 11)
You may also be interested in...
Premier Laser/Ophthalmic Imaging Systems
Premier would acquire the 49% of ophthalmic digital imaging system maker OIS that it does not currently own under an agreement announced Oct. 22. While OIS had previously rejected as inadequate a Premier offer of $0.85 worth of Premier stock for each OIS share, the revised agreement would provide roughly $1.78 per share. OIS shareholders, which have yet to approve the pact, would receive 0.8 shares of Premier common stock per OIS share; Premier closed at 2-7/32 the day before the announcement. The two firms had first planned to merge under a February 1998 agreement, which was subsequently dissolved (1"The Gray Sheet" June 28, p. 21)
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip